Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421655 · ClinicalTrials.gov registry record · Phase 3
A Trial of Grazax in Subjects With Hayfever
A Phase 3 study, sponsored by ALK-Abelló A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT00421655 is a Phase 3 study that has completed, run by ALK-Abelló A/S. The registered enrollment target is 329 participants.
The verdict
NCT00421655, a Phase 3 study, has completed, sponsored by ALK-Abelló A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
Interventions
- DRUG Grazax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421655
The ClinicalTrials.gov registry entry for NCT00421655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALK-Abelló A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Grazax is the first listed.
NCT00421655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421655 about?
NCT00421655 is a clinical study titled "A Trial of Grazax in Subjects With Hayfever". The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
What is the current status of trial NCT00421655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2006-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00421655?
The interventions under investigation include: Grazax (DRUG).
Who is sponsoring clinical trial NCT00421655?
This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.